2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow AVP-923-20: new trials by email Literature Review of AVP-923-20 trials Research Report on AVP-923-20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease AVP-923-20, Placebo, AVP-923-30 - Agitation, Alzheimer's Disease | Phase 2 | Completed | Avanir Pharmaceuticals | 220 | 2012-08-13 | 2021-11-26 |
| Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis AVP-923-45, AVP-923-30, AVP-923-20 - Central Neuropathic Pain, Multiple Sclerosis | Phase 2 | Completed | Avanir Pharmaceuticals | 209 | 2011-09-08 | 2021-11-22 |
Aggression (1) · Alzheimer Disease (1) · Multiple Sclerosis (1) · Psychomotor Agitation (1)
United States (2) · Argentina (1) · Czechia (1) · Poland (1) · Spain (1)